Table 1 Baseline characteristics of patients with and without PLND in overall cohort and propensity-score matched cohort.
Characteristics | Overall cohort | Propensity-score matched cohort | ||||
|---|---|---|---|---|---|---|
No PLND (n = 4267) | PLND (n = 16401) | p value | No PLND (n = 4267) | PLND (n = 4267) | p value | |
Age, years, n (%) | ||||||
<70 | 3687 (86.4%) | 14084 (85.9%) | 0.37 | 3687 (86.4%) | 3716 (87.1%) | 0.355 |
≥70 | 580 (13.6%) | 2317 (14.1%) | 580 (13.6%) | 551 (12.9%) | ||
Race, n (%) | ||||||
Black | 647 (15.2%) | 2290 (14.0%) | <0.001 | 647 (15.2%) | 659 (15.4%) | 0.809 |
White | 3418 (80.1%) | 12852 (78.4%) | 3418 (80.1%) | 3396 (79.6%) | ||
Others | 202 (4.7%) | 1259 (7.6%) | 202 (4.7%) | 212 (5.0%) | ||
D’Amico risk stratification, n (%) | ||||||
Low | 366 (8.6%) | 369 (2.3%) | <0.001 | 366 (8.6%) | 364 (8.5%) | 0.975 |
Intermediate | 2658 (62.3%) | 7463 (45.5%) | 2658 (62.3%) | 2668 (62.5%) | ||
High | 1243 (29.1%) | 8569 (52.2%) | 1243 (29.1%) | 1235 (29.0%) | ||
Clinical T stage, n (%) | ||||||
≤T2 | 4080 (95.6%) | 15289 (93.2%) | <0.001 | 4080 (95.6%) | 4051 (94.9%) | 0.139 |
≥T3 | 187 (4.4%) | 1112 (6.8%) | 187 (4.4%) | 216 (5.1%) | ||
PSA, ng/ml, n (%) | ||||||
≤20 | 4039 (94.7%) | 14462 (88.2%) | <0.001 | 4039 (94.7%) | 4020 (94.2%) | 0.370 |
>20 | 228 (5.3%) | 1939 (11.8%) | 228 (5.3%) | 247 (5.8%) | ||
Pathological T stage, n (%) | ||||||
≤T2 | 2837 (66.5%) | 8261 (50.4%) | <0.001 | 2837 (66.5%) | 2811 (65.9%) | 0.552 |
≥T3 | 1430 (33.5%) | 8140 (49.6%) | 1430 (33.5%) | 1456 (34.1%) | ||
Gleason score at biopsy, n (%) | ||||||
≤7 | 3649 (85.5%) | 10268 (62.6%) | <0.001 | 3649 (85.5%) | 3668 (86.0%) | 0.556 |
≥8 | 618 (14.5%) | 6133 (37.4%) | 618 (14.5%) | 599 (14.0%) | ||
Gleason score at RP, n (%) | ||||||
≤7 | 3766 (88.3%) | 12093 (73.7%) | <0.001 | 3766 (88.3%) | 3755 (88.0%) | 0.713 |
≥8 | 501 (11.7%) | 4308 (26.3%) | 501 (11.7%) | 512 (12.0%) | ||
Number of removed nodes, median (range) | ||||||
6 (1–70) | 6 (1–66) | |||||
Lymph node invasion, n (%) | ||||||
1681 (10.2%) | 250 (5.9%) | |||||
